Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients

被引:22
|
作者
Molto, Jose [1 ]
Santos, Jose R. [1 ]
Perez-Alvarez, Nuria [1 ,3 ]
Cedeno, Samandhy [2 ]
Miranda, Cristina [1 ]
Khoo, Saye [5 ]
Else, Laura [5 ]
Llibre, Josep Maria [1 ]
Valle, Marta [4 ]
Clotet, Bonaventura [1 ,2 ]
机构
[1] Hosp Univ Germans Trias & Pujol, Lluita SIDA Fdn, Badalona, Spain
[2] Hosp Univ Germans Trias & Pujol, IrsiCaixa Fdn, Badalona, Spain
[3] Univ Politecn Barcelona, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Inst Recerca, Ctr Invest Medicament, Barcelona, Spain
[5] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1128/AAC.00520-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of < 50 copies/ml at week 48. The trough concentrations of darunavir in plasma, the number of darunavir resistance mutations, the change in the 50% inhibitory concentration (IC50) of darunavir in the virtual phenotype, and the darunavir gIQ and vIQ were correlated with the virological outcome in regression analyses adjusted by the number of active drugs in the background regimen. The VL was < 50 copies/ml in 56.8% of patients at week 48. Changes in the VL were not significantly associated with the darunavir concentration (P = 0.304), the number of darunavir resistance mutations (P = 0.695), or the change in the IC50 (P = 0.750). However, patients with darunavir vIQs of >= 1.5 had a 12-fold greater chance of achieving a >= 1 log(10) reduction in the VL (odds ratio [OR], 12.7; 95% confidence interval [95% CI], 1.9 to 81.6; P = 0.007), and a 5-fold greater chance of achieving a VL of < 50 copies/ml (OR, 5.4; 95% CI, 1.2 to 24.5; P = 0.028), at week 48 than patients with darunavir vIQs of < 1.5. The positive and negative predictive values of this darunavir vIQ cutoff for achieving a VL of < 50 copies/ml at week 48 were 70% and 69%, respectively. The darunavir vIQ predicts virological response to darunavir-based salvage therapy better than the darunavir trough concentration or resistance mutations alone. We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression.
引用
收藏
页码:3928 / 3932
页数:5
相关论文
共 34 条
  • [31] Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response
    Corma-Gomez, Anais
    Macias, Juan
    Morano, Luis
    Rivero, Antonio
    Tellez, Francisco
    Jose Rios, Maria
    Santos, Marta
    Serrano, Miriam
    Palacios, Rosario
    Merino, Dolores
    Miguel Real, Luis
    De Los Santos, Ignacio
    Vera-Mendez, Francisco J.
    Jose Galindo, Maria
    Pineda, Juan A.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (05) : E96 - E102
  • [32] Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: Does it affect long-term treatment outcome?
    Jensen-Fangel, S
    Pedersen, C
    Nielsen, H
    Tauris, P
    Moller, A
    Sorensen, HT
    Obel, N
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (10) : 743 - 749
  • [33] Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals
    Moron-Lopez, Sara
    Navarro, Jordi
    Jimenez, Montse
    Rutsaert, Sofie
    Urrea, Victor
    Puertas, Maria C.
    Torrella, Ariadna
    De Clercq, Laura
    Ribas, Bibiana Planes
    Galvez, Cristina
    Salgado, Maria
    Vandekerckhove, Linos
    Blanco, Julia
    Crespo, Manel
    Martinez-Picado, Javier
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (08) : 1320 - 1328
  • [34] Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting A retrospective cohort study
    Jacobson, Karen
    Ogbuagu, Onyema
    MEDICINE, 2018, 97 (43)